The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX – Free Report) from a neutral rating to a buy rating in a ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

HSBC boosted their price target on shares of BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. HC Wainwright raised their price ...

In a report released yesterday, Chris Shibutani from Goldman Sachs upgraded BioNTech SE (BNTX – Research Report) to a Buy, with a price ...

The revised price target reflects the company's near-term revenue ... as they could potentially enhance the company's position in the cancer treatment market. BioNTech's stock performance will likely ...

TD Cowen has maintained a Hold rating on BioNTech (NASDAQ: NASDAQ:BNTX), while increasing the stock's price target to $132 from $85. The adjustment reflects an updated financial model projecting ...

Operator Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz ...

Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...